Pharmaceutical Products In Development

NanaBisTM

Status: In clinical Trial

Purpose: Adjuvant and/or replacement therapy to opioids in advanced cancer pain

Descriptive: TO BE UPDATED SHORTLY

Proposed Regulatory Pathway: Australian S8 Specialist led.

NanaBidialTM

Status: In clinical trial

Purpose: For CINV and seizures

Descriptive: TO BE UPDATED SHORTLY

Proposed Regulatory Pathway: Australian S4 , GP led

NanoStatTM

Status: In Bio-equivelance

Purpose: For the treament of elevated cholestrol

Descriptive: TO BE UPDATED SHORTLY

Proposed Regulatory Pathway: Australian S4 , GP led

NanUlinTM

Status: HREC aaproved trial forthcoming

Purpose: For type 2 diabetics

Descriptive: TO BE UPDATED SHORTLY

Proposed Regulatory Pathway: Australian S4 , GP led

NanoTestTM

Status: HREC approval trial forthcoming

Purpose: For increasing low testosterone levels in men

Descriptive: TO BE UPDATED SHORTLY

Proposed Regulatory Pathway: Australian S4 , GP led

NanoCelle FexodenadineTM

Status: At Bench

Purpose: For convenience and faster absorption

Descriptive: TO BE UPDATED SHORTLY

Proposed Regulatory Pathway: Australian S4 , GP led

NRGBioticTM

Status: In clinical trial [Phase 2]

Purpose: For TD patients on SSRI's

Descriptive: TO BE UPDATED SHORTLY

Proposed Regulatory Pathway: Australian S4 , GP led

ORSBioticTM

Status: In trial development

Purpose: TO BE UPDATED SHORTLY

Descriptive: TO BE UPDATED SHORTLY

Proposed Regulatory Pathway: Australian S4 , GP led

T2BioticTM

Status: In clinical trial

Purpose: For treatment of pre-diabetic patients

Descriptive: TO BE UPDATED SHORTLY

Proposed Regulatory Pathway: Australian S4 , GP led

MultiBioticTM

Status: In trial development

Purpose: For the treament of Non Alcoholic Fatty Liver Disease (NAFLD) and NASH

Descriptive: TO BE UPDATED SHORTLY

Proposed Regulatory Pathway: Australian S4 , GP led